We’re refreshing!

Come experience the new website and submit your feedback. The current site will temporarily
remain available as we make the final adjustments to the new online experience.

Click here to check it out. ►
1 888 2 DONATE(1 888 236-6283)
Find a Clinic:  search Search this site:  search
Book an appointment
Home > What Should I Know? > Safety and Testing
Facebook youTube Twitter flickr
Why Should I Donate?
Who Needs Blood?
Can I donate?
Basic Eligibility
Donor Questionnaire
Malaria policy
Donation Date Calculator
American Sign Language
What Can I Donate?
Types of Donations
Plasma & Platelets
Stem Cells
Financial Gifts
Blood for Research
How Can I Get Involved?
In My Community
Send an e-card
Public Involvement
Partners for Life
What's Your Type
Sign Up to Learn More
Young Blood For Life
Assignment Saving Lives
National Blood Donor Week
What Should I Know?
Pandemic Preparedness
Safety and Testing
Research & Development
West Nile Virus (WNV)
Transfusion Related Acute Lung Injury (TRALI)
vCJD Travel Deferral
Become a Volunteer
New Donor Form
Change Your Address
Join OneMatch
Become a Partner for Life Organization
Become a Partner for Life Member
Join Ready, Set... Give!
Donor Experience Survey
Customer Service
Circular of Information
Customer Letters
Plasma Protein Products
Hospital Customer Forms
Resource Library
OneMatch Documents
Adverse Events
Diagnostic Services

Nucleic Acid Testing

Nucleic Acid Testing (NAT) is a method of testing blood that is more sensitive than conventional tests that require the presence of antibodies to trigger a positive test result.

On October 25, 1999 Canadian Blood Services implemented NAT screening of all blood donations for Hepatitis C Virus (HCV). On May 28, 2001 it broadened its NAT screening to include NAT screening for HIV-1, the virus that causes AIDS. Canadian Blood Services intends to implement another NAT screen test for West Nile Virus (WNV) on or about July 1, 2003.

NAT works by detecting the low levels of viral genetic material present when an infection occurs but before the body begins producing antibodies in response to a virus.

NAT significantly reduces the 'window period' or the time between donor exposure to the virus and the appearance of antibodies. By decreasing the window period, it allows for earlier detection of the infection and thus further decreases the possibility of transmission via transfusion.

Since implementation of HCV NAT screening, there has been only one "window case" detected, and for HIV-1 NAT there have been no window cases detected as of May 2003.

NAT HCV Scientific Paper Questions and Answers
NAT HIV Scientific Paper pdf: 25K/8 pages
NAT HIV Investigational Project (General Document) and Qs&As pdf: 25K/9 pages
Frequently Asked Questions
News Releases
Health Canada

Safety and Testing
Safety and Testing
The Screening Process
False Positive Results
Nucleic Acid Testing
Blood Safety

Top of the page Privacy and Access to Information | Terms of Use | Copyright © 1998-2014 Canadian Blood Services. All rights reserved.